Trials / Conditions / Atherosclerotic Cardiovascular Disease (ASCVD)

Atherosclerotic Cardiovascular Disease (ASCVD)

18 registered clinical trials studyying Atherosclerotic Cardiovascular Disease (ASCVD) — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-A NCT07355894	Stanford University	N/A
Not Yet Recruiting	Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases NCT07311330	Beijing Inno Medicine Co., Ltd.	Phase 2
Not Yet Recruiting	Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Manage NCT07208331	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	—
Recruiting	Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study) NCT06960902	Nantes University Hospital	N/A
Recruiting	Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) NCT07157774	Eli Lilly and Company	Phase 3
Completed	A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overwe NCT07141914	Novo Nordisk A/S	—
Recruiting	Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease NCT06930885	Hospital do Coracao	Phase 3
Recruiting	Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and NCT06813911	Novartis Pharmaceuticals	Phase 3
Completed	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World NCT06874751	Novo Nordisk A/S	—
Completed	A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Pat NCT06589791	Novo Nordisk A/S	—
Recruiting	The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study NCT07315997	Brigham and Women's Hospital	—
Active Not Recruiting	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obe NCT06383390	Eli Lilly and Company	Phase 3
Completed	A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a NCT06322641	Novo Nordisk A/S	—
Active Not Recruiting	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Ad NCT06292013	Eli Lilly and Company	Phase 3
Terminated	VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN) NCT05834673	Monash University	N/A
Completed	A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMma NCT05755373	Novo Nordisk A/S	—
Completed	Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations Wit NCT07196280	Chinese PLA General Hospital	—
Available	Managed Access Programs for TQJ230, Pelacarsen NCT07000695	Novartis Pharmaceuticals	—